- Home
- ITOC vs BRTX Comparison
ITOC vs BRTX Comparison
Compare ITOC & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITOC | BRTX |
|---|---|---|
| Founded | 1998 | 1997 |
| Country | China | United States |
| Employees | 7 | N/A |
| Industry | | Managed Health Care |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 6.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ITOC | BRTX |
|---|---|---|
| Price | $0.33 | $0.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.8M | ★ 23.0M |
| Earning Date | 03-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.16 |
| 52 Week High | $1.15 | $1.89 |
Technical Indicators
Market Signals| Indicator | ITOC | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 59.50 |
| Support Level | $0.29 | $0.20 |
| Resistance Level | $0.41 | $1.20 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 4.01 | 49.78 |
Price Performance
Historical ComparisonAbout ITOC iTonic Holdings Ltd Class A Ordinary Shares
iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. Its product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device, etc.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.